Avaliçao clínica e imunoistoquímica de tumores mamários em cadelas submetidas a tratamento com inibidor da cicloxogenase-2 (Firocoxibe)
Carregando...
Data
2012-12-17
Autores
Elston, Flávio [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
Tumores mamários expressam a enzima cicloxigenase (Cox-2), que caracteriza um processo inflamatório intenso e pode também demonstrar a presença de alterações paraneoplásicas. Este trabalho teve por objetivo estudar a expressão de Cox-2 em tumores mamários de cadelas e avaliar o efeito do anti-inflamatório firocoxibe sobre a mesma. Os animais selecionados foram divididos em dois grupos: controle (9 animais) e tratado (10 animais). As cadelas foram avaliadas por exame clínico, bioquímica sérica, tamanho, volume, localização e avaliação TNM dos tumores e avaliação da qualidade de vida. O grupo tratado recebeu o firocoxibe na dosagem de 5mg/kg ao dia por sete dias e após este período todos os animais foram novamente avaliados e submetidos à mastectomia. As amostras obtidas nos dois momentos foram avaliadas por exame histológico e imunoistoquímica para expressão de Cox-2. Os resultados mostraram que, embora não tenha havido diferença no tamanho do maior nódulo ou na expressão de COX -2 entre os grupos após o tratamento, o aumento na expressão de COX-2 observado no grupo controle não foi verificado no grupo tratado e que os animais que receberam o tratamento por 7 dias apresentaram diminuição dos níveis de proteínas séricas totais (p=0.00588) e aumento dos níveis séricos de uréia (p=0.01388). Estes resultados sugerem que o uso do firocoxibe como coadjuvante no tratamento de cadelas com neoplasia mamária submetidas à mastectomia pode ser benéfico para deter a evolução da doença, embora seja indicado o acompanhamento dos animais para garantir que não haja sangramento gastrintestinal e que a saúde seja preservada
Breast tumors express the enzyme cycloxygenase (COX-2), characterizing an inflammatory process and also demonstrate the presence of paraneoplastic alterations. This experiment aimed to study the expression of Cox-2 in mammary tumors of dogs and to evaluate the effect of anti-inflammatory firocoxib on it. The selected animals were divided into two groups: control (9 animals) and treated (10 animals). The animals were evaluated by clinical examination, serum biochemistry, size, volume, location and TNM evaluation of tumors and assessment of quality of life. The treatment group received firocoxib at dosage of 5mg/kg daily for seven days and after this period all animals were re-evaluated and submitted to mastectomy. The samples obtained at both moments were evaluated by histology and immunohistochemistry for the expression of Cox-2. The results showed that, although there was no difference in size of the largest tumor or in the expression of COX-2 between the groups after treatment, increased expression of COX-2 seen in the control group was not observed in the treated group and that those animals that received firocoxib for 7 days showed decreased levels of total serum protein (p = 0.00588) and increased serum levels of urea (p = 0.01388). These results suggest that the use of firocoxib as adjuvant therapy for dogs with breast cancer submitted to mastectomy can be beneficial to halt the progression of the disease, although monitoring of animals is indicated to ensure there is no gastrointestinal bleeding and health is preserved
Breast tumors express the enzyme cycloxygenase (COX-2), characterizing an inflammatory process and also demonstrate the presence of paraneoplastic alterations. This experiment aimed to study the expression of Cox-2 in mammary tumors of dogs and to evaluate the effect of anti-inflammatory firocoxib on it. The selected animals were divided into two groups: control (9 animals) and treated (10 animals). The animals were evaluated by clinical examination, serum biochemistry, size, volume, location and TNM evaluation of tumors and assessment of quality of life. The treatment group received firocoxib at dosage of 5mg/kg daily for seven days and after this period all animals were re-evaluated and submitted to mastectomy. The samples obtained at both moments were evaluated by histology and immunohistochemistry for the expression of Cox-2. The results showed that, although there was no difference in size of the largest tumor or in the expression of COX-2 between the groups after treatment, increased expression of COX-2 seen in the control group was not observed in the treated group and that those animals that received firocoxib for 7 days showed decreased levels of total serum protein (p = 0.00588) and increased serum levels of urea (p = 0.01388). These results suggest that the use of firocoxib as adjuvant therapy for dogs with breast cancer submitted to mastectomy can be beneficial to halt the progression of the disease, although monitoring of animals is indicated to ensure there is no gastrointestinal bleeding and health is preserved
Descrição
Palavras-chave
Cão - Doenças, Mamas - Cancer, Oncologia veterinaria, Agentes anti-inflamatorios, Veterinary oncology, Breast - Cancer
Como citar
ELSTON, Flávio. Avaliçao clínica e imunoistoquímica de tumores mamários em cadelas submetidas a tratamento com inibidor da cicloxogenase-2 (Firocoxibe). 2012. 56 f. Dissertação (mestrado) - Universidade Estadual Paulista Júlio de Mesquita Filho, Faculdade de Medicina Veterinária e Zootecnia, 2012.